05:57 PM EDT, 06/25/2024 (MT Newswires) -- Kiniksa Pharmaceuticals ( KNSA ) said Tuesday Samsung Biologics has agreed to perform technology transfer, process performance qualification, manufacturing and supply services for the supply of the company's Arcalyst drug substance.

Under the terms of a product specific agreement between the parties, Kiniksa has committed to purchase process performance qualification and pre-approval inspection batches of Arcalyst, according to a regulatory filing.

The company said it is also obligated to buy additional batches of the product in a five-year period through 2031.

The companies also signed a master services agreement that will have a 10-year initial term and will automatically renew for terms of two years, according to the filing.